Alnylam Pharmaceuticals, Inc. vs Raytheon Technologies Corp — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223.29 (market cap $29.60B), while Raytheon Technologies Corp trades at $222.44 (market cap $301.71B). The key difference: Raytheon Technologies Corp is far larger — about 10.2× Alnylam Pharmaceuticals, Inc.'s market cap, and Raytheon Technologies Corp pays a 1.3% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | RTX | |
|---|---|---|
Market Cap | $29.60B | $301.71B |
Sector | Health | Industrials |
52-Week High | $491.22 | $224.12 |
52-Week Low | $205.48 | $151.75 |
Enterprise Value | $27.56B | $332.26B |
Dividend Yield | — | 1.3% |
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
RTX trades at $224.12, up 0.49% today, near its 52-week high. The stock shows strong technical momentum with bullish moving averages and support at $223. Fundamentally, revenue grew to $88.6B in 2025 with net income of $6.73B, and recent contract wins like the $515M SPY-6 radar award bolster growth prospects. Earnings have consistently beaten estimates, with Q2 2026 EPS of $1.89 exceeding expectations.
The outlook is positive given robust defense spending and operational execution, but valuation multiples like a P/E of 39.41 pose risks if growth slows. Analyst consensus is bullish with a $233.14 price target, though overbought RSI levels suggest near-term consolidation may occur. Key risks include execution delays and macroeconomic pressures on defense budgets.
Trailing returns across standard periods
Latest headlines on both assets
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →Raytheon Technologies is a diversified aerospace and defense industrial company formed from the merger of United Technologies and Raytheon, with roughly equal exposure as a supplier to commercial aerospace manufactures and to the defense market as a prime and subprime contractor.
Read more on RTX →